<DOC>
	<DOCNO>NCT00548496</DOCNO>
	<brief_summary>This study design test safety effectiveness SB-751689 treatment distal radius fracture post-menopausal woman men comparison placebo determine healing time fracture decrease .</brief_summary>
	<brief_title>A Phase IIa Study Of Men And Post-Menopausal Women With A Fractured Distal Radius</brief_title>
	<detailed_description />
	<mesh_term>Fractures , Bone</mesh_term>
	<criteria>fracture/broken distal radius bone conservative treatment include close reduction immobilization device men ( &gt; 35 year &lt; 80 ) postmenopausal woman ( &lt; 80 yr ) Full In/Ex crit . EPs per Amendment 1 , date 7 Feb 08 Subject willing able provide write informed consent Unilateral , extraarticular distal radius fracture AO/ASIF type 23A2 23A3 permissible . ( Arbeitsgemeinschaft für Osteosynthesefragen [ AO ] / Association Study Internal Fixation [ ASIF ] ) . Multiple fracture bone , limb distal radius fracture , permissible subject perform protocolrequired procedure . Received conservative treatment distal radius fracture , include closed reduction immobilization device ( cast , splint , brace ) Ambulatory male female subject age ≥35 &lt; 80 year age sustain close , unilateral , fracture distal radius 5 day prior randomization . Females non childbearing potential define : &gt; 1 year postmenopausal , &gt; 1 year spontaneous amenorrhea &gt; 1 year post surgical bilateral oophorectomy . Use follicle stimulate hormone [ FSH ] level &gt; 40mIU/mL confirm surgical postmenopausal status , bilateral oophorectomy status uncertain . Females childbearing potential must negative urine bhCG pregnancy test Screening visit agree practice acceptable highly effective method birth control throughout duration study . Highly effective birth control method include preventative measure take avoid pregnancy failure rate le 1 % per year . Subject , opinion investigator , willing able comply requirement protocol , include ability understand patient report outcome ( PRO ) questionnaires fracture occur within 5 day injury AO B Ctype prior fracture wrist placement hardware ( pin plate ) diseases affect bone metabolism inflammatory joint disease increase risk osteosarcoma malignant disease diagnose within previous 5 year ( except resect basal cell cancer ) past current history liver disease know hepatic biliary abnormality treatment fluoride ( dose great 10 mg/day ) within previous 5 year osteoporosis limitation prior treatment oral bisphosphonate Any treatment fracture distal radius occur 5 day fracture sustain injury All B Ctype fracture ( intraarticular ) accord AO Fracture classification distal radius fracture would likely require open reduction internal fixation . All additional fracture limb ( include hand humerus ) distal radial fracture exclude . Any fracture contralateral upper low arm , wrist hand would interfere obtain measurement dynamometer exclude . Pathological ( tumorrelated ) fracture Prior fracture wrist adult Hardware include pin plate wrist ( either prior current injury ) History concurrent synovial pseudoarthrosis , congenital pseudoarthrosis , active osteomyelitis History concurrent diseases affect bone metabolism ( e.g. , osteomalacia , hyperparathyroidism , etc . ) History skeletal immaturity Active disease history inflammatory joint disease ( e.g. , rheumatoid arthritis , lupus , psoriatic arthritis ) would interfere image fracture Subjects receive thyroid hormone replacement therapy thyroid stimulate hormone ( TSH ) level measured.Subjects exclude TSH level &lt; 0.1 &gt; 10.0 mIU/L . However , subject exclude TSH range 0.14.5 mIU/L . If TSH &gt; 4.5 £10.0 mIU/L , measure T4 exclude subject T4 outside normal range History active nephrolithiasis ( kidney stone ) Subjects increase risk osteosarcoma Paget 's disease bone history prior external beam implant radiation therapy involve skeleton Malignant disease diagnose within previous 5 year ( except resect basal cell cancer ) Active history malabsorption ( e.g. , history celiac disease , irritable bowel syndrome , inflammatory bowel disease ) Note : Subjects exclude previous active gastrointestinal disease ( i.e. , prior history nonrecurrent peptic ulcer disease ) . Symptoms dyspepsia , Gastroesophageal Reflux Disease ( GERD ) must able control occasional use ( 3 dos per week ) histamine2 receptor antagonist Past current history liver disease know hepatic biliary abnormality ( exception previously document diagnosis Gilbert 's syndrome ) Drug alcohol abuse ( past current ) within previous 12 month A history risk factor Torsades de Pointes ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) A marked baseline prolongation correct QT interval ( e.g. , QTc interval ³450 msec Screening ECG correct either Bazett 's Fridericia 's methodology ) Surgical medical condition : Presence follow condition within 6 month prior screen : myocardial infarction , coronary bypass surgery , coronary artery angioplasty , unstable angina , clinically evident congestive heart failure , cardiac pacemaker , cerebrovascular accident : currently know , suspect , history neurological disease affect clinical assessment heal ; Cardiac arrhythmia : significant cardiac arrhythmia show screen ECG ( confirm eRT report ) , know suspected history significant cardiac arrhythmia 's within 6 month prior screen . i.e. , preexcitation syndrome , sinus pause &gt; 3 second , nonsustained ventricular tachycardia ( ³3 consecutive ectopic beat ) , sustain ventricular tachycardia ( ³30 consecutive ectopic beat ) , sustain supraventricular tachycardia ( ³30 consecutive ectopic beat ) , accessory pathway tachycardia , bradycardia ( heart rate &lt; 50 beat per minute ) , atrial flutter , atrial fibrillation , ectopic pacemaker , sick sinus syndrome , atrioventricular block ( second third degree ) , bundle branch block . Any clinically relevant biological abnormality find and/or volunteer screening ( related disease investigation ) , opinion investigator , clinically significant would preclude safe participation study [ e.g. , human immunodeficiency virus infection significant mental illness ] Inability swallow whole tablet Any previous treatment strontium ranelate intravenous bisphosphonate Any previous treatment oral bisphosphonate follow : treatment within last 6 month ; ≥ 1 month cumulative treatment within last 12 month ; ≥ 3 month cumulative treatment within past 2 year , ≥ 2 year cumulative treatment within past 5 year Treatment fluoride ( dose great 10mg/day ) within previous 5 year osteoporosis Treatment PTH , PTH analogues similar anabolic agent osteoporosis within last 2 year Treatment drug affect bone metabolism within last 6 month prior screen : Chronic systemic corticosteroid ( e.g. , glucocorticoid , mineralocorticoid ) treatment 2 intraarticular injection within past year use oral , parenteral , longterm , highdose inhaled corticosteroid . Treatment topical corticosteroid exclude subject participating ; Hormones ( e.g. , estrogens/ '' natural estrogen preparation '' [ except nonsystemic vaginal treatment ] , 19norprogestins , selective estrogen receptor modulators [ SERMs ] raloxifene , anabolic steroids/androgens dehydroepiandrosterone [ DHEA ] sulfate form [ DHEAS ] , nandrolone , tibolone , active vitamin D analogs/metabolites prescribed treatment osteoporosis condition 1,25dihydroxy vitamin D [ calcitriol ] 1alphahydroxyvitamin D3 [ 1alpha hydroxycholecalciferol ] , calcitonin ) ; Calcineurin inhibitor ( e.g. , cyclosporine , tacrolimus ) methotrexate Contraindications therapy calcium vitamin D Any subject receive treatment macrolide antibiotic : clarithromycin , erythromycin , telithromycin , troleandomycin within 2 day prior Baseline visit Administration investigational drug within 90 day precede first dose study medication Current treatment potent Pglycoprotein and/or potent CYP3A inhibitor prohibit : Diltiazem verapamil ; oral azole antifungal ( e.g. , ketoconazole , itraconazole , fluconazole ) ; Cyclosporine oral tacrolimus ; Ritonavir ; Quinidine ; Nefazodone Concomitant therapy proton pump inhibitor ( e.g. , esomeprazole , lansoprazole , omeprazole , pantoprazole , rabeprazole ) prohibit . Daily , chronic use ( &gt; 3 dos per week ) histamine2 receptor antagonist ( e.g. , cimetidine , famotidine , nizatidine , ranitidine ) prohibit . Antacids administer within 2 hour ( ) administration study medication . Vitamin A excess 10,000 IU per day , heparin , lithium , anticonvulsant medication ( except benzodiazepine ) Current therapy digoxin Subjects take daily , longterm ( i.e. , &gt; 1 year ) nonsteroidal antiinflammatory drug ( NSAIDs ) diseases inflammatory arthritis exclude . The use low dose aspirin prevention heart disease permit . Short term use NSAIDs permit acute pain management use alternative , nonNSAIDs encourage Total serum calcium level outside local laboratory reference range Screening visit Liver chemistry ( aspartate aminotransferase [ AST ] , alanine aminotransferase [ ALT ] , total bilirubin ) exceed 2‑fold upper limit local laboratory reference range Screening visit Glomerular filtration rate ( GFR ) &lt; 35 mL/min calculate Modification Diet Renal Disease ( MDRD ) equation follow : GFR ( mL/min/1.73 m2 ) = 186 x ( Serum creatinine mg/dL ) 1.154 x ( Age ) 0.203 x ( 0.742 female ) x ( 1.210 African American ) ( conventional unit ) Women pregnant breastfeeding allow study . Females childbearing potential must negative urine bhCG pregnancy test Screening Randomization visit agree practice acceptable highly effective method birth control duration study 4 week follow last dose study medication . Highly effective birth control method include preventative measure take avoid pregnancy failure rate le 1 % per year .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>fracture wrist</keyword>
	<keyword>Distal radial fracture ,</keyword>
</DOC>